Holen Sie sich die Stockscreener-App
6.52
1.51%
-0.10
Handel nachbörslich:
6.60
0.08
+1.23%
Schlusskurs vom Vortag:
$6.62
Offen:
$6.61
24-Stunden-Volumen:
22,787
Relative Volume:
0.41
Marktkapitalisierung:
$186.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
-6.86%
6M Leistung:
+141.48%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.24
$6.69
1-Wochen-Bereich:
$6.24
$6.9731
52-Wochen-Spanne:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Vergleichen Sie IMDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.52 | 189.76M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), NewAmsterdam Pharma Company (NAMS) and Resmed (RMD) - The Globe and Mail
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$8.13m - simplywall.st
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - marketscreener.com
Insight ‘congratulated’ STAR working group on organ health testing paper - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Boston Scientific (BSX) - The Globe and Mail
iMDx Announces 'JPM Week” and 'BTIG Snowbird” Conference Participation - The Manila Times
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - Sahm
Is Insight Molecular Diagnostics Inc. (7OC0) stock considered safe haven2026 world cup usa national team quarterfinals midfield engines low block defense group prediction preview - Улправда
Needham reiterates Buy rating on Insight Molecular stock, cites progress on GraftAssureDx - Investing.com Nigeria
Insight Molecular Diagnostics Inc. Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - marketscreener.com
Insight Molecular Diagnostics (IMDX) Nears Key FDA Submission Mi - GuruFocus
IMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - MarketScreener
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - Sahm
iMDx Stock Rebounds After-Hours As Study Shows Transplant Test Works As Well As Market Standard - MSN
Prostate Cancer Diagnostics Market Size Report, 2026 – 2035 - Global Market Insights Inc.
Insight Molecular Diagnostics Inc.Common Stock (NQ: IMDX - FinancialContent
KIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics Platform - newarkadvocate.com
Insiders Rewarded With US$5.2m Addition To Investment As Insight Molecular Diagnostics Stock Hits US$183m - Yahoo Finance
Molecular Cytogenetics Market Analysis Reveals Growth - openPR.com
Insight Molecular (IMDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Insight Molecular Diagnostics (FRA:7OC0) EV-to-OCF : -5.98 (As of Dec. 24, 2025) - GuruFocus
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11% - simplywall.st
Animal Health Market Size, Share & Industry Trends Analysis Report [2032] - Fortune Business Insights
Why Insight Molecular Diagnostics Inc. (7OC0) stock attracts HNW investorsQuarterly Risk Review & Verified Short-Term Trading Plans - DonanımHaber
Biosensors Market Size, Share & Analysis | Growth Report [2032] - Fortune Business Insights
United States Molecular Diagnostics Market Trends & Summary - vocal.media
Page not foundFactor Thisâ„¢ - FinancialContent
Is Insight Molecular Diagnostics Inc. (7OC0) stock suitable for passive index fundsJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
Is Insight Molecular Diagnostics Inc. (7OC0) stock a safe buy pre earningsMarket Sentiment Review & Safe Capital Preservation Plans - Newser
Will Insight Molecular Diagnostics Inc. (7OC0) stock sustain dividend payoutsOptions Play & Real-Time Volume Trigger Notifications - Newser
Why global investors buy Insight Molecular Diagnostics Inc. (7OC0) stock2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - Newser
Why Insight Molecular Diagnostics Inc. (7OC0) stock stays resilientMarket Movers & Real-Time Buy Zone Alerts - Newser
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Es liegen keine Finanzdaten für Insight Molecular Diagnostics Inc (IMDX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):